antibody development

With over 40% of therapeutic drugs targets currently being membrane-associated proteins, the study of monoclonal antibodies for both immunodiagnostic biomarkers and therapies is a large growth area in the pharmaceutical industry.

Antibody discovery and development is a time-intensive and costly process that involves screening of large candidate libraries and hit confirmation, as well as humanisation and functional characterisation of leads in vitro, even before preclinical testing in animal models for efficacy and toxicity.

The requirement for fast, accurate cell-based screening assays in a high throughput screening environment is paramount in today’s pharmaceutical industry and research consortiums. Here, rapid and sensitive screening of libraries for these antibodies is central to the drug development programme enabling the production of high quality, well characterised antibodies.

TTP Labtech’s mirrorball represents a viable solution being applicable throughout the entire antibody discovery process from primary screening, clone selection and affinity maturation.

mirrorball’s mix-and-read or no-wash assays offer significant advantages, providing rapid and robust data whilst remaining cost efficient due to decreased sample and reagent usage. mirrorball provides high detection sensitivity and statistically robust data from every cell, as its whole well scanning capabilities allow for uneven distribution of cell populations within a well. mirrorball has been applied to the most common antibody species including whole IgG, scFV and Fab.

In addition, mirrorball enables multiplexed assays which allow for the simultaneous assessment of antibody binding and specificity in a single test. This drives down screening costs whilst offering unrivalled throughput and sensitivity.

Efficient cell and bead multiplexing – MedImmune case study

England, E. et al from MedImmune have evaluated a selection of typical cell- and bead- based assays that demonstrate how the multilaser capability of the mirrorball can be exploited to develop highly sensitive multiplex assays. This allows for identifying antibody cross-reactivity and selectivity but significantly without the loss of throughput. In this study the multiplexing of two antibody–cell binding assays (using different dyes) and three cytokine quantitation bead assays (using the same dye at different intensities) was developed. The results demonstrated an improvement of the sensitivity and efficiency of biologics screening

related products

related app notes

related posters